PLYGF (PolyPeptide Group AG) Total Equity: $398.8 Mil (As of Dec. 2025)


PLYGF PolyPeptide Group AG PLYGF
56 GF Score
Price $43.00
GF Value $26.83
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Total Equity?

PolyPeptide Group AG PLYGF 56 Total Equity is $398.8 Mil as of Dec. 2025. GuruFocus rates PLYGF with a GF Score™ of 56/100 and a GF Value™ of $26.83 (Significantly Overvalued). The stock has 8 warning signs investors should review.

PolyPeptide Group AG's total equity for the quarter that ended in Dec. 2025 was $398.8 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

PolyPeptide Group AG Total Equity Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Total Equity Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 475.90 446.69 415.73 374.08 398.83

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 415.73 387.42 374.08 381.76 398.83
PLYGF
56GF Score
PolyPeptide Group AG PLYGF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

PolyPeptide Group AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=967.165-568.338
=398.8

PolyPeptide Group AG's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=967.165-568.338
=398.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $398.8 Mil mean?
PolyPeptide Group AG (PLYGF) has a Total Equity of $398.8 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Total Equity too high?
PolyPeptide Group AG's current Total Equity is $398.8 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Total Equity compare to ZTS and UTHR?
PolyPeptide Group AG's Total Equity of $398.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Total Equity is $398.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (PLYGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.83, compared to a current price of $43.00 — trading 60.3% above its estimated fair value. The current Total Equity is $398.8 Mil. PolyPeptide Group AG's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For PolyPeptide Group AG (PLYGF), the current Total Equity is $398.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (PLYGF) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of $43.00 is trading 60.3% above its estimated GF Value™ of $26.83. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for PLYGF:

  • Total Equity: $398.8 Mil
  • GF Value™: $26.83 vs. price of $43.00 (60.3% above fair value)
  • GF Score™: 56/100 with 8 warning signs

No single metric tells the full story. See the PLYGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
56GF Score

Get the complete analysis for PLYGF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.00
Price
$26.83
GF Value